6996 (6996) News
Follow 6996 (6996) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 2 public stories across 2 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Antengene doses first patient in Phase III CLINCH-3 trial
Antengene said the first patient has been dosed in its pivotal Phase III CLINCH-3 study evaluating ATG-022.
EQUITY | Sep 21, 2026, 12:30 AM UTC
L
Nichicon to buy back up to 2,248,000 shares, 3.35% of outstanding
Nichicon Corp plans to repurchase up to 2,248,000 shares, representing 3.35% of its outstanding shares, according to TradingView News.
EQUITY | Sep 02, 2026, 07:46 AM UTC